Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

(2009) T.-I Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of the Fused NS4A Peptide−NS3 Protease Domain To Study the Importance of the Helicase Domain for Protease Inhibitor Binding to Hepatitis C Virus NS3-NS4A

(2009) Diane Thibeault et al.   BIOCHEMISTRY

Macrocyclic inhibitors of HCV NS3 protease

(2009) Srikanth Venkatraman et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)

(2009) T. L. Kieffer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of resistance mutations against HCV ketoamide protease inhibitors

(2008) X TONG et al.   ANTIVIRAL RESEARCH

Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors

(2008) Pierre Raboisson et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors

(2008) Sandrine Vendeville et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350

(2008) Pierre Raboisson et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The emerging field of HCV drug resistance

(2008) Gennadiy Koev et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease

(2008) Nigel J. Liverton et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The exploration of macrocycles for drug discovery — an underexploited structural class

(2008) Edward M. Driggers et al.   NATURE REVIEWS DRUG DISCOVERY